BCL2 and central nervous system cancer: Such findings are particularly pertinent in light of studies which demonstrate that overexpression of the anti-apoptotic proteins, Bcl-2 or Bcl-xL, neither of which are capable of binding Noxa, had no effect on subsequent combined R-roscovitine and TRAIL treatment in glioma cells [34].